Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The recent clinical study update from Eli Lilly and Company, in collaboration with ALX Oncology Inc., focuses on a Phase 2/3 trial titled ‘A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)’. The study aims to evaluate the efficacy of Evorpacept in combination with other drugs for patients with advanced HER2+ gastric cancer, highlighting its potential significance in improving treatment outcomes for this challenging condition.
The study tests Evorpacept (ALX148), a drug administered intravenously every two weeks, in combination with Trastuzumab, Ramucirumab, and Paclitaxel. These interventions target HER2-overexpressing gastric cancer, aiming to enhance treatment efficacy and patient survival rates.
This interventional study employs a randomized, parallel assignment model with a quadruple masking approach in its Phase 3 segment, although the sponsor has decided not to proceed with this phase. The primary purpose is treatment, focusing on patients who have progressed after prior therapies.
The study commenced on January 15, 2022, with its primary completion and estimated overall completion dates yet to be disclosed. The last update was submitted on August 5, 2025, indicating ongoing progress and adjustments in the study’s trajectory.
This update could influence Eli Lilly’s stock performance and investor sentiment, as advancements in cancer treatment often drive market interest. With the decision to halt Phase 3, strategic implications for Eli Lilly and its competitors may arise, affecting their positions in the oncology market.
The study is ongoing, with further details accessible on the ClinicalTrials portal.